Research ExplorerPublicationsTroponin I and cardiovascular risk prediction in the general...

Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium

Standard

Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium. / Blankenberg, Stefan; Salomaa, Veikko; Makarova, Nataliya; Ojeda, Francisco; Wild, Philipp; Lackner, Karl J; Jørgensen, Torben; Thorand, Barbara; Peters, Annette; Nauck, Matthias; Petersmann, Astrid; Vartiainen, Erkki; Veronesi, Giovanni; Brambilla, Paolo; Costanzo, Simona; Iacoviello, Licia; Linden, Gerard; Yarnell, John; Patterson, Christopher C; Everett, Brendan M; Ridker, Paul M; Kontto, Jukka; Schnabel, Renate B; Koenig, Wolfgang; Kee, Frank; Zeller, Tanja; Kuulasmaa, Kari; BiomarCaRE Investigators.

In: EUR HEART J, Vol. 37, No. 30, 07.08.2016, p. 2428-37.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Blankenberg, S, Salomaa, V, Makarova, N, Ojeda, F, Wild, P, Lackner, KJ, Jørgensen, T, Thorand, B, Peters, A, Nauck, M, Petersmann, A, Vartiainen, E, Veronesi, G, Brambilla, P, Costanzo, S, Iacoviello, L, Linden, G, Yarnell, J, Patterson, CC, Everett, BM, Ridker, PM, Kontto, J, Schnabel, RB, Koenig, W, Kee, F, Zeller, T, Kuulasmaa, K & BiomarCaRE Investigators 2016, 'Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium', EUR HEART J, vol. 37, no. 30, pp. 2428-37. https://doi.org/10.1093/eurheartj/ehw172

APA

Blankenberg, S., Salomaa, V., Makarova, N., Ojeda, F., Wild, P., Lackner, K. J., Jørgensen, T., Thorand, B., Peters, A., Nauck, M., Petersmann, A., Vartiainen, E., Veronesi, G., Brambilla, P., Costanzo, S., Iacoviello, L., Linden, G., Yarnell, J., Patterson, C. C., ... BiomarCaRE Investigators (2016). Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium. EUR HEART J, 37(30), 2428-37. https://doi.org/10.1093/eurheartj/ehw172

Vancouver

Blankenberg S, Salomaa V, Makarova N, Ojeda F, Wild P, Lackner KJ et al. Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium. EUR HEART J. 2016 Aug 7;37(30):2428-37. https://doi.org/10.1093/eurheartj/ehw172

Bibtex

@article{6a6c5fb8d55044ad8210246561b4afc4,
title = "Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium",
abstract = "AIMS: Our aims were to evaluate the distribution of troponin I concentrations in population cohorts across Europe, to characterize the association with cardiovascular outcomes, to determine the predictive value beyond the variables used in the ESC SCORE, to test a potentially clinically relevant cut-off value, and to evaluate the improved eligibility for statin therapy based on elevated troponin I concentrations retrospectively.METHODS AND RESULTS: Based on the Biomarkers for Cardiovascular Risk Assessment in Europe (BiomarCaRE) project, we analysed individual level data from 10 prospective population-based studies including 74 738 participants. We investigated the value of adding troponin I levels to conventional risk factors for prediction of cardiovascular disease by calculating measures of discrimination (C-index) and net reclassification improvement (NRI). We further tested the clinical implication of statin therapy based on troponin concentration in 12 956 individuals free of cardiovascular disease in the JUPITER study. Troponin I remained an independent predictor with a hazard ratio of 1.37 for cardiovascular mortality, 1.23 for cardiovascular disease, and 1.24 for total mortality. The addition of troponin I information to a prognostic model for cardiovascular death constructed of ESC SCORE variables increased the C-index discrimination measure by 0.007 and yielded an NRI of 0.048, whereas the addition to prognostic models for cardiovascular disease and total mortality led to lesser C-index discrimination and NRI increment. In individuals above 6 ng/L of troponin I, a concentration near the upper quintile in BiomarCaRE (5.9 ng/L) and JUPITER (5.8 ng/L), rosuvastatin therapy resulted in higher absolute risk reduction compared with individuals <6 ng/L of troponin I, whereas the relative risk reduction was similar.CONCLUSION: In individuals free of cardiovascular disease, the addition of troponin I to variables of established risk score improves prediction of cardiovascular death and cardiovascular disease.",
keywords = "Biomarkers, Cardiovascular Diseases, Europe, Humans, Prognosis, Prospective Studies, Risk Assessment, Risk Factors, Troponin I",
author = "Stefan Blankenberg and Veikko Salomaa and Nataliya Makarova and Francisco Ojeda and Philipp Wild and Lackner, {Karl J} and Torben J{\o}rgensen and Barbara Thorand and Annette Peters and Matthias Nauck and Astrid Petersmann and Erkki Vartiainen and Giovanni Veronesi and Paolo Brambilla and Simona Costanzo and Licia Iacoviello and Gerard Linden and John Yarnell and Patterson, {Christopher C} and Everett, {Brendan M} and Ridker, {Paul M} and Jukka Kontto and Schnabel, {Renate B} and Wolfgang Koenig and Frank Kee and Tanja Zeller and Kari Kuulasmaa and {BiomarCaRE Investigators}",
note = "{\textcopyright} The Author 2016. Published by Oxford University Press on behalf of the European Society of Cardiology.",
year = "2016",
month = aug,
day = "7",
doi = "10.1093/eurheartj/ehw172",
language = "English",
volume = "37",
pages = "2428--37",
journal = "EUR HEART J",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "30",

}

RIS

TY - JOUR

T1 - Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium

AU - Blankenberg, Stefan

AU - Salomaa, Veikko

AU - Makarova, Nataliya

AU - Ojeda, Francisco

AU - Wild, Philipp

AU - Lackner, Karl J

AU - Jørgensen, Torben

AU - Thorand, Barbara

AU - Peters, Annette

AU - Nauck, Matthias

AU - Petersmann, Astrid

AU - Vartiainen, Erkki

AU - Veronesi, Giovanni

AU - Brambilla, Paolo

AU - Costanzo, Simona

AU - Iacoviello, Licia

AU - Linden, Gerard

AU - Yarnell, John

AU - Patterson, Christopher C

AU - Everett, Brendan M

AU - Ridker, Paul M

AU - Kontto, Jukka

AU - Schnabel, Renate B

AU - Koenig, Wolfgang

AU - Kee, Frank

AU - Zeller, Tanja

AU - Kuulasmaa, Kari

AU - BiomarCaRE Investigators

N1 - © The Author 2016. Published by Oxford University Press on behalf of the European Society of Cardiology.

PY - 2016/8/7

Y1 - 2016/8/7

N2 - AIMS: Our aims were to evaluate the distribution of troponin I concentrations in population cohorts across Europe, to characterize the association with cardiovascular outcomes, to determine the predictive value beyond the variables used in the ESC SCORE, to test a potentially clinically relevant cut-off value, and to evaluate the improved eligibility for statin therapy based on elevated troponin I concentrations retrospectively.METHODS AND RESULTS: Based on the Biomarkers for Cardiovascular Risk Assessment in Europe (BiomarCaRE) project, we analysed individual level data from 10 prospective population-based studies including 74 738 participants. We investigated the value of adding troponin I levels to conventional risk factors for prediction of cardiovascular disease by calculating measures of discrimination (C-index) and net reclassification improvement (NRI). We further tested the clinical implication of statin therapy based on troponin concentration in 12 956 individuals free of cardiovascular disease in the JUPITER study. Troponin I remained an independent predictor with a hazard ratio of 1.37 for cardiovascular mortality, 1.23 for cardiovascular disease, and 1.24 for total mortality. The addition of troponin I information to a prognostic model for cardiovascular death constructed of ESC SCORE variables increased the C-index discrimination measure by 0.007 and yielded an NRI of 0.048, whereas the addition to prognostic models for cardiovascular disease and total mortality led to lesser C-index discrimination and NRI increment. In individuals above 6 ng/L of troponin I, a concentration near the upper quintile in BiomarCaRE (5.9 ng/L) and JUPITER (5.8 ng/L), rosuvastatin therapy resulted in higher absolute risk reduction compared with individuals <6 ng/L of troponin I, whereas the relative risk reduction was similar.CONCLUSION: In individuals free of cardiovascular disease, the addition of troponin I to variables of established risk score improves prediction of cardiovascular death and cardiovascular disease.

AB - AIMS: Our aims were to evaluate the distribution of troponin I concentrations in population cohorts across Europe, to characterize the association with cardiovascular outcomes, to determine the predictive value beyond the variables used in the ESC SCORE, to test a potentially clinically relevant cut-off value, and to evaluate the improved eligibility for statin therapy based on elevated troponin I concentrations retrospectively.METHODS AND RESULTS: Based on the Biomarkers for Cardiovascular Risk Assessment in Europe (BiomarCaRE) project, we analysed individual level data from 10 prospective population-based studies including 74 738 participants. We investigated the value of adding troponin I levels to conventional risk factors for prediction of cardiovascular disease by calculating measures of discrimination (C-index) and net reclassification improvement (NRI). We further tested the clinical implication of statin therapy based on troponin concentration in 12 956 individuals free of cardiovascular disease in the JUPITER study. Troponin I remained an independent predictor with a hazard ratio of 1.37 for cardiovascular mortality, 1.23 for cardiovascular disease, and 1.24 for total mortality. The addition of troponin I information to a prognostic model for cardiovascular death constructed of ESC SCORE variables increased the C-index discrimination measure by 0.007 and yielded an NRI of 0.048, whereas the addition to prognostic models for cardiovascular disease and total mortality led to lesser C-index discrimination and NRI increment. In individuals above 6 ng/L of troponin I, a concentration near the upper quintile in BiomarCaRE (5.9 ng/L) and JUPITER (5.8 ng/L), rosuvastatin therapy resulted in higher absolute risk reduction compared with individuals <6 ng/L of troponin I, whereas the relative risk reduction was similar.CONCLUSION: In individuals free of cardiovascular disease, the addition of troponin I to variables of established risk score improves prediction of cardiovascular death and cardiovascular disease.

KW - Biomarkers

KW - Cardiovascular Diseases

KW - Europe

KW - Humans

KW - Prognosis

KW - Prospective Studies

KW - Risk Assessment

KW - Risk Factors

KW - Troponin I

U2 - 10.1093/eurheartj/ehw172

DO - 10.1093/eurheartj/ehw172

M3 - SCORING: Journal article

C2 - 27174290

VL - 37

SP - 2428

EP - 2437

JO - EUR HEART J

JF - EUR HEART J

SN - 0195-668X

IS - 30

ER -